Catalyst
Slingshot members are tracking this event:
Esperion Therapeutics set to launch global cardiovascular outcomes trial (CVOT) on bempedoic acid on major cardiovascular events for high-risk cardiovascular disease (CVD) patients by first half of 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 18, 2019
Occurred Source:
https://investor.esperion.com/news-releases/news-release-details/esperion-announces-late-breaking-presentation-final-results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Global Cardiovascular Outcomes Trial, Bempedoic Acid, Cardiovascular Disease
